硫嘌呤与甲氨蝶呤:炎症性肠病治疗中耐受性与停药率的比较
该回顾性队列研究纳入2004年1月1日至2016年12月31日两家医院开始免疫调节剂治疗的782例炎症性肠病(IBD)患者,比较硫嘌呤与甲氨蝶呤的长期耐受性和持续用药情况。甲氨蝶呤组因不良事件停药率显著高于硫嘌呤组(40% vs 19%,P < 0.001),停药发生时间较晚但未达统计学显著(中位7 vs 5个月,P = 0.08)。结论为甲氨蝶呤停药率是剂量优化硫嘌呤治疗的两倍。
要点
- 甲氨蝶呤组因不良事件停药率40%,显著高于硫嘌呤组的19%(P < 0.001)。
- 恶心(18% vs 4%)、乏力(7% vs 2%)和肝毒性(8% vs 2%)在甲氨蝶呤组更常见(各P < 0.001)。
- 因不良事件住院(0.8% vs 0.9%)、严重感染(9% vs 12%)和死亡(1% vs 0%)两组相当(各P > 0.05)。
核心结论
- 甲氨蝶呤因不良事件停药率是剂量优化硫嘌呤治疗的两倍(40% vs 19%,P < 0.001)。
研究设计与样本
- 2004年1月1日至2016年12月31日在两家医院开展的回顾性队列研究,纳入开始硫嘌呤或甲氨蝶呤治疗的782例IBD患者。
- 甲氨蝶呤联合叶酸组244例(31%),其中67%为皮下给药;硫嘌呤组538例(69%),其中73%为硫唑嘌呤。
- 甲氨蝶呤组中位剂量为每周25 mg;硫嘌呤组中位6-TGN为298 pmol/8×10^8红细胞。
- 中位随访时间甲氨蝶呤组42个月 vs 硫嘌呤组47个月(P = 0.09)。
主要发现
- 甲氨蝶呤组较硫嘌呤组有更高比例的既往免疫调节剂不耐受史(54% vs 3%)、年龄更大(中位43 vs 36岁)、病程更长(中位6 vs 5年),各P < 0.05。
- 总体208例(27%)因不良事件停药,甲氨蝶呤组40% vs 硫嘌呤组19%(P < 0.001)。
- 不良事件包括恶心(18% vs 4%)、乏力(7% vs 2%)和肝毒性(8% vs 2%),各P < 0.001。
- 因不良事件住院(0.8% vs 0.9%)、严重感染(9% vs 12%)和死亡(1% vs 0%)两组相当(各P > 0.05)。
- 甲氨蝶呤组因不良事件停药发生较晚(中位7 vs 5个月,P = 0.08)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are safety concerns regarding immunomodulators (thiopurines and methotrexate) for treatment of inflammatory bowel disease (IBD). AIM: To compare the long-term tolerability, and persistence of thiopurine and methotrexate therapy in IBD. METHODS: A retrospective cohort study was performed at two hospitals between 1 January 2004 and 31 December 2016 for patients commenced on thiopurines or methotrexate for IBD. Treatment discontinuation rates, intolerances and disease activity were obtained from medical records. RESULTS: There were 782 patients commenced on immunomodulator therapy; 244 (31%) on methotrexate with folate (67% subcutaneous therapy) and 538 (69%) on thiopurine (73% azathioprine). Median follow-up was 42 vs 47 months (P = 0.09). In patients on thiopurines, median 6-TGN was 298 pmol/8 x 108 RBCs, while the median dose of methotrexate was 25 mg weekly. Methotrexate recipients had a higher rate of prior immunomodulator intolerance, were typically older and had a longer disease duration (54% vs 3%, median 43 vs 36 years, 6 vs 5 years, respectively, each P < 0.05). Overall, 208 (27%) discontinued therapy due to adverse events, (40% on methotrexate vs 19% on thiopurines, P < 0.001), including nausea (18% vs 4%), fatigue (7% vs 2%) and hepatotoxicity (8% vs 2%, each P < 0.001). Hospitalisations from adverse events (0.8% vs 0.9%) and serious infections (9% vs 12%), and deaths (1% vs 0%) were comparable between groups (all P > 0.05). Discontinuation due to adverse events occurred later in patients on methotrexate than on thiopurines (median 7 vs 5 months, P = 0.08). CONCLUSION: Discontinuation of methotrexate occurred at rates twice that of dose-optimised thiopurine therapy.
引用
- Vasudevan A, Parthasarathy N, Con D, et al. Thiopurines vs methotrexate: Comparing tolerability and discontinuation rates in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2020. PMID: 32794599. doi:10.1111/apt.16039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。